Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial
Condition(s):Chronic Intestinal Pseudo-obstructionLast Updated:June 21, 2021Unknown status
Hide Studies Not Open or Pending
Condition(s):Chronic Intestinal Pseudo-obstructionLast Updated:June 21, 2021Unknown status
Condition(s):Chronic Intestinal Pseudo ObstructionLast Updated:August 9, 2017Completed
Condition(s):Intestinal Pseudo-Obstruction; Fecal Microbiota TransplantationLast Updated:August 31, 2023Completed
Condition(s):Chronic Intestinal Pseudo-ObstructionLast Updated:November 19, 2008Completed
Condition(s):Chronic Intestinal Pseudo-obstructionLast Updated:February 13, 2023Active, not recruiting
Condition(s):Chronic Intestinal Pseudo-ObstructionLast Updated:February 7, 2024Recruiting
Condition(s):Intestinal Pseudo-Obstruction; Short Bowel Syndrome; Malabsorption Syndrome Autoimmune Enteropathy; Bacterial OvergrowthLast Updated:June 23, 2023Recruiting
Condition(s):Gastrointestinal Motility DisorderLast Updated:November 22, 2021Unknown status
Condition(s):Systemic SclerosisLast Updated:April 16, 2013Completed
Condition(s):Cholestasis; Prematurity; Gastroschisis; Intestinal Atresia; Necrotizing EnterocolitisLast Updated:November 23, 2015Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.